Cargando…

Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France

BACKGROUND: This study compares annual ambulatory care expenditures per patient with type 2 diabetes mellitus (T2DM) in France according to treatment phase and renal function status. METHODS: Records from patients with T2DM were extracted from a health insurance database. Patients were classified in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guelfucci, Florent, Clay, Emilie, Aballéa, Samuel, Lassalle, Régis, Moore, Nicholas, Toumi, Mondher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653727/ https://www.ncbi.nlm.nih.gov/pubmed/23627403 http://dx.doi.org/10.1186/1472-6823-13-15

Ejemplares similares

Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA
por: Aballéa, Samuel, et al.
Publicado: (2013)

An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models
por: Pochopień, Michał, et al.
Publicado: (2021)

Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach
por: Han, Ru, et al.
Publicado: (2021)

Determinants of orphan drugs prices in France: a regression analysis
por: Korchagina, Daria, et al.
Publicado: (2017)

A prospective study of health care resource utilisation and selected costs of schizophrenia in France
por: Sarlon, Emmanuelle, et al.
Publicado: (2012)

Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
por: Toumi, Mondher, et al.
Publicado: (2020)

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

Current process and future path for health economic assessment of pharmaceuticals in France
por: Toumi, Mondher, et al.
Publicado: (2015)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
por: Toumi, Mondher, et al.
Publicado: (2017)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
por: Zhou, Junwen, et al.
Publicado: (2019)

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
por: Pochopien, Michal, et al.
Publicado: (2019)

Measuring the health-related quality of life in young children: how far have we come?
por: Germain, Nicola, et al.
Publicado: (2019)

Factors influencing the COVID-19 daily deaths' peak across European countries
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
por: Bowrin, Kevin, et al.
Publicado: (2020)

Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and z-drugs consumption in nine European countries
por: Clay, Emilie, et al.
Publicado: (2012)

Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
por: Hawken, Natalia, et al.
Publicado: (2017)

On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

New drug regulations in France: what are the impacts on market access? Part 1 – Overview of new drug regulations in France
por: Rémuzat, Cécile, et al.
Publicado: (2013)

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
por: Aballéa, Samuel, et al.
Publicado: (2014)

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
por: Kragh, Nana, et al.
Publicado: (2022)

Quality of life is predictive of relapse in schizophrenia
por: Boyer, Laurent, et al.
Publicado: (2013)

A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments
por: Massetti, Marc, et al.
Publicado: (2015)

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
por: Chachoua, Lylia, et al.
Publicado: (2020)

New drug regulations in France: what are the impacts on market access? Part 2 – impacts on market access and impacts for the pharmaceutical industry
por: Rémuzat, Cécile, et al.
Publicado: (2013)

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial
por: Trouiller, Jean-Baptiste, et al.
Publicado: (2022)

Market access pathways for cell therapies in France
por: Rémuzat, Cécile, et al.
Publicado: (2015)

Social Preferences for Orphan Drugs: A Discrete Choice Experiment Among the French General Population
por: Toumi, Mondher, et al.
Publicado: (2020)

Conflict of interest in Health Technology Assessment decisions: case law in France and impact on reimbursement decisions
por: Frybourg, Sandrine, et al.
Publicado: (2015)

Elicitation of Health-related Quality-of-life Concepts Associated with Overactive Bladder: A Qualitative Study
por: Hawken, Natalia, et al.
Publicado: (2016)

Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis
por: Millier, Aurelie, et al.
Publicado: (2011)

Patient survey to identify reasons for non-adherence and elicitation of quality of life concepts associated with immunosuppressant therapy in kidney transplant recipients
por: Muduma, Gorden, et al.
Publicado: (2016)

Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study
por: Clay, Emilie, et al.
Publicado: (2019)

Pharmaceutical expenditure forecast model to support health policy decision making
por: Rémuzat, Cécile, et al.
Publicado: (2014)

EU pharmaceutical expenditure forecast
por: Urbinati, Duccio, et al.
Publicado: (2014)

Novel methodology for pharmaceutical expenditure forecast
por: Vataire, Anne-Lise, et al.
Publicado: (2014)

Systematic literature reviews over the years
por: Smela, Beata, et al.
Publicado: (2023)

Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies
por: Dabbous, Omar, et al.
Publicado: (2022)

The quality of life of Spanish patients with Huntington's disease measured with H-QoL-I and EQ-5D
por: Dorey, Julie, et al.
Publicado: (2016)

Modelling the consequences of a reduction in alcohol consumption among patients with alcohol dependence based on real-life observational data
por: Rahhali, Nora, et al.
Publicado: (2015)

Rapid literature review: definition and methodology
por: Smela, Beata, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p6gj7e0e22nlmr0jd8a60q4pqc